IPO Year In Review: Record-Year Bodes Well For 2021, And For More SPACs

86 Drug Developers Raised $17bn, Generated 86% Average Return

 
• By Mandy Jackson

Biopharma was an attractive investment in 2020 and fundamentals are unchanged in 2021, including the pandemic’s work-at-home requirements, which allowed more companies to go public faster.

Pixelated acronym IPO made from cubes, mosaic pattern
Out of 86 companies that went public last year, 67 were trading above their IPO values as of 27 January • Source: Shutterstock

More from Financing

More from Business